Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

45.85 -0.37 (-0.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,668,400
Open 46.26
Bid (Size) 45.00 (100)
Ask (Size) 46.92 (100)
Prev. Close 46.22
Today's Range 45.24 - 47.06
52wk Range 32.99 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused... 
Via Finterra
Topics Economy Intellectual Property
News headline image
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire

Performance

YTD
+20.0%
+20.0%
1 Month
-42.6%
-42.6%
3 Month
-35.9%
-35.9%
6 Month
-32.8%
-32.8%
1 Year
-24.0%
-24.0%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
From Pomerantz LLP
Via GlobeNewswire
Corcept Therapeutics Inc (NASDAQ:CORT) Fits the Affordable Growth Profile ↗
Via Chartmill
News headline image
2 Stocks Under $50 to Target This Week and 1 We Turn Down
Via StockStory
News headline image
Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 Facing Headwinds
Via StockStory
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
1 Safe-and-Steady Stock to Target This Week and 2 That Underwhelm
Via StockStory
News headline image
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT
From DJS Law Group
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Incorporated on Behalf of Corcept Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
1 Healthcare Stock to Target This Week and 2 We Turn Down
Via StockStory
Topics Stocks
News headline image
CORCEPT THERAPEUTICS is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Via TheNewswire.com
News headline image
CORCEPT THERAPEUTICS is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Via NewMediaWire
News headline image
Why Corcept (CORT) Stock Is Trading Lower Today
Via StockStory
News headline image
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations
Via NewMediaWire
News headline image
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations
Via TheNewswire.com
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 45.85
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 01/28/26 04:00 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 5.32B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.